Pharma News

KT-253 by Kymera Therapeutics for Solid Tumor: Likelihood of Approval

Photo of MEEFRO MEEFRO Send an email November 6, 2023
0 124,534 Less than a minute

KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Solid Tumor.

Source link
#KT253 #Kymera #Therapeutics #Solid #Tumor #Likelihood #Approval

Photo of MEEFRO MEEFRO Send an email November 6, 2023
0 124,534 Less than a minute
Photo of MEEFRO

MEEFRO

Related Articles

What is the current valuation of AstraZeneca’s Sabestomig

April 16, 2024

What is the current valuation of AbbVie’s ABBV-400

April 16, 2024

What is the current valuation of Merck’s MK-1084

April 16, 2024

What is the current valuation of AstraZeneca’s AZD-9574

April 16, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *